Response of human tumour xenografts to fractionated X-irradiation.
The response of two human tumour xenografts to single dose and fractionated X-rays has been tested using regrowth delay as the assay. The tumours were line transplanted cells from a moderately well-differentiated squamous carcinoma of the tonsillar fossa (XJ) and an undifferentiated carcinoma of the floor of the mouth (XR). Comparison of the dose response curves for single doses in air, clamped, or after misonidazole administration, led to estimates of the hypoxic fraction (approximately 15%) and the sensitizer enhancement ratio (less than or equal to 1.6). When 5 daily fractions were used, the effect of misonidazole (miso) was lost and reoxygenation appeared to be effective in both tumours. Comparison of single doses and 5 fractions in clamped tumours, and in those sensitized by miso, allowed the sparing effect of fractionation to be estimated. When analysed by the linear quadratic model the alpha/beta ratios were found to be in the range of 6.4-9.2 Gy and 6.8-16.0 Gy for the two tumours. These values are in good agreement with murine tumours (assayed in vivo or in vitro), with human tumour cells assayed in vitro, and with analyses of fractionated clinical data for skin cancer.
D000818:Animals; D002277:Carcinoma / Q000188:drug therapy / Q000532:radiotherapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D008819:Mice, Nude; D008920:Misonidazole / Q000627:therapeutic use; D009062:Mouth Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D009368:Neoplasm Transplantation; D010778:Photochemotherapy; D011879:Radiotherapy Dosage; D014067:Tonsillar Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D014183:Transplantation, Heterologous
D008920:Misonidazole